US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Provident

16.37

-0.2700-1.62%

Post-market: 16.370.00000.00%16:22 EDT

Volume:611.10K

Turnover:10.00M

Market Cap:2.14B

PE:13.78

High:16.56

Open:16.30

Low:16.13

Close:16.64

Loading ...

Overview Company News Filings

3 Intriguing US Stocks Estimated To Be Undervalued By Up To 46.6%

Simply Wall St.

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

February 2025's US Stocks That Could Be Trading Below Estimated Value

Simply Wall St.

3 US Stocks Estimated To Be Trading Below Intrinsic Value In February 2025

Simply Wall St.

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Storytel Among 3 Companies Estimated To Be Trading Below Intrinsic Value

Simply Wall St.

3 Companies Possibly Trading Below Estimated Fair Value

Simply Wall St.

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

Press Release: Provident Bank Strengthens Executive Leadership Team, Welcoming Chief Lending Officer to Advance Commercial Banking and Lending Strategy

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

Hot Chili Confirms Major Cu-Au Porphyry Discovery at La Verde

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Wildcat Resources Says Preliminary Feasibility Study 50% Complete for West Australian Lithium Project

MT Newswires Live

KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System

3 Dividend Stocks In US With Yields Up To 8.3%

Simply Wall St.

Resources Top 5: Investors pile in on AusQuest as it confirms copper-gold discovery

Akora Resources confirms DSO upgrade potential at Bekisopa iron ore project

PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PFS/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PFS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident","latestPrice":16.37,"timestamp":1746043200000,"preClose":16.64,"halted":0,"volume":611099,"hourTrading":{"tag":"盘后","latestPrice":16.37,"preClose":16.37,"latestTime":"16:22 EDT","volume":54146,"amount":886373.497996,"timestamp":1746044526342},"delay":0,"floatShares":126167377,"shares":130663184,"eps":1.188092,"marketStatus":"Closed","change":-0.27,"latestTime":"04-30 16:00:00 EDT","open":16.3,"high":16.56,"low":16.125,"amount":10002958.956259,"amplitude":0.026142,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.188092,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746086400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":16.64,"dividendRate":0.058644,"preHourTrading":{"tag":"盘前","latestPrice":16.55,"preClose":16.64,"latestTime":"04:15 EDT","volume":1,"amount":16.55,"timestamp":1746000914544},"postHourTrading":{"tag":"盘后","latestPrice":16.37,"preClose":16.37,"latestTime":"16:22 EDT","volume":54146,"amount":886373.497996,"timestamp":1746044526342},"volumeRatio":0.745676,"impliedVol":0.0617,"impliedVolPercentile":0.092},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","floatShares":126167377,"roa":"0.77%","roe":"6.77%","lyrEps":1.053397,"volumeRatio":0.745676,"shares":130663184,"dividePrice":0.96,"high":16.56,"amplitude":0.026142,"preClose":16.64,"low":16.125,"week52Low":13.07,"pbRate":"0.80","psRate":"3.05","week52High":22.24,"institutionHeld":0.6698,"latestPrice":16.37,"eps":1.188092,"divideRate":0.058644,"volume":611099,"delay":0,"ttmEps":1.188092,"open":16.3,"prevYearClose":18.87,"prevWeekClose":16.54,"prevMonthClose":17.17,"prevQuarterClose":17.17,"fiveDayClose":16.37,"twentyDayClose":17.19,"sixtyDayClose":18.23},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PFS\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2511269594","title":"3 Intriguing US Stocks Estimated To Be Undervalued By Up To 46.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511269594","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511269594?lang=en_us&edition=fundamental","pubTime":"2025-02-14 22:02","pubTimestamp":1739541745,"startTime":"0","endTime":"0","summary":"As U.S. stock markets hover near record highs, recent fluctuations in retail sales data and treasury yields have captured investor attention, highlighting the complex interplay of economic indicators influencing market dynamics. In this environment, identifying undervalued stocks can be particularly appealing to investors seeking opportunities that may offer potential value relative to current market conditions.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Overview: Celsius Holdings, Inc. is engaged in the development, processing, marketing, distribution, and sale of functional energy drinks and liquid supplements across various international markets with a market cap of approximately $5 billion.Celsius Holdings, trading at US$22.66, is considered undervalued with a fair value estimate of US$42.43, reflecting a 46.6% discount. Despite recent legal challenges related to inventory overselling to Pepsi and potential sales declines, Celsius anticipates robust revenue ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-intriguing-us-stocks-estimated-140225804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0034390439.USD","CELH","BK4089","IE0031619046.USD","IE00B7SZL793.SGD","MMI","BK4134","IE00B66KJ199.SGD","PFS","CSTM","IE00B19Z6F94.USD","BK4153","KD","BK4211","BK4079","ATEX","BK4195","IE00B19Z4B17.USD","SYM"],"gpt_icon":1},{"id":"2511569349","title":"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2511569349","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511569349?lang=en_us&edition=fundamental","pubTime":"2025-02-14 22:00","pubTimestamp":1739541600,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 14, 2025  -- February 14, 2025– IN8bio, Inc. , a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy  Meetings in Hawaii. The data, previously announced, reinforce INB-100’s potential to significantly reduce post-transplant relapse in high-risk acute myeloid leukemia  patients, positioning this gamma-delta T cell therapy as a promising approach in hematologic oncology.The latest findings demonstrate that INB-100 continues to deliver long-term remissions, with no AML patient relapses observed to date with a median follow-up of 20.1 months. The 1-year progression-free survival  rate across all leukemia patients stands at 90.9%, and 1-year overall survival  is 100%, outperforming real-world historical controls. These data demonstrate that results for INB-100 do not appear to be due to imbalances in pa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/in8bio-presents-positive-phase-1-140000114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","BK4211","CRS","OS","BK4139","BK4539","BK4195","BK4097","INAB","LU2065731478.USD","IE00B7SZL793.SGD","PFS","IE00B19Z4B17.USD","IE0031619046.USD","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2511668411","title":"February 2025's US Stocks That Could Be Trading Below Estimated Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2511668411","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511668411?lang=en_us&edition=fundamental","pubTime":"2025-02-14 18:02","pubTimestamp":1739527365,"startTime":"0","endTime":"0","summary":"As U.S. stock markets approach record highs, driven by a deceleration in wholesale inflation and a tempered approach to tariffs, investors are keenly observing opportunities for potential value investments. In this environment, identifying stocks that may be trading below their estimated value can offer strategic entry points for those looking to capitalize on market inefficiencies and long-term growth prospects.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Overview: Advanced Micro Devices, Inc. is a global semiconductor company with a market capitalization of approximately $181.04 billion.Our earnings growth report unveils the potential for significant increases in Advanced Micro Devices' future results.Dive into the specifics of Advanced Micro Devices here with our thorough financial health report.Sociedad Química y Minera de Chile  is trading at US$40.17, significantly below its estimated fair value of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/february-2025s-us-stocks-could-100245529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","BK4096","SGXZ23171101.USD","BK4123","BK4079","AMD","IE0031619046.USD","BK4141","BK4566","MMI","IE0034390439.USD","BK4554","LU1880398554.USD","LU2458330169.SGD","LU0719512351.SGD","SQM","IE00B5949003.HKD","BK4585","LU0823421333.USD","LU0082616367.USD","BK4543","BK4534","LU1861214812.USD","LU1988902786.USD","LU0198837287.USD","PFS","BK4211","LU1169589451.USD","LU1951200564.SGD","GFS","LU0505663152.USD","LU1989764748.USD","CSTM","IE00BMPRXR70.SGD","BK4109","KD","LU0072463663.USD","LU1064131342.USD","BK4605","TRU","IE00BMPRXN33.USD","LU1852331112.SGD","IE00B66KJ199.SGD","BK4529","IE00B7SZL793.SGD","LU1951198990.SGD","BK4545","LU0889565833.HKD","LU0109392836.USD","LU2360106780.USD"],"gpt_icon":1},{"id":"2511523990","title":"3 US Stocks Estimated To Be Trading Below Intrinsic Value In February 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2511523990","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511523990?lang=en_us&edition=fundamental","pubTime":"2025-02-13 22:02","pubTimestamp":1739455345,"startTime":"0","endTime":"0","summary":"As the United States market navigates through a period of fluctuating inflation rates and evolving monetary policies, investors are keenly observing stock futures that have shown modest upticks following recent economic data releases. In this environment, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for those looking to capitalize on market inefficiencies.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Adeia is trading at US$12.96, significantly below its estimated fair value of US$18.76, suggesting potential undervaluation based on cash flows. Recent multi-year IP agreements with companies like Fetch TV and Roku highlight its strong market position in digital entertainment technology. However, despite expected earnings growth of 81.9% annually, profit margins have declined from last year and interest payments are not well covered by earnings, indicating financial challenges that investors should consider caref","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-us-stocks-estimated-trading-140225925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","BK4195","IE00B66KJ199.SGD","BK4539","BK4588","RSI","CSTM","FVRR","BK4097","PFS","BK4122","BK4130","BK4134","BK4150","ADEA","IE0031619046.USD","BK4585","IE00B7SZL793.SGD","BK4153","BK4023","IE00B19Z4B17.USD","SMWB","KD"],"gpt_icon":0},{"id":"2511439985","title":"IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2511439985","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511439985?lang=en_us&edition=fundamental","pubTime":"2025-02-13 19:05","pubTimestamp":1739444700,"startTime":"0","endTime":"0","summary":"Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025. 95 patients enrolled in neoadjuvant UM trial and targeting clinical data and regulatory update in H1 2025, including vision data in plaque brachytherapy patients. Targeting median OS readout in ~40 1L MUM patients in 2025. Targeting expansion of study in Q1 2025 of IDE397 in combination with Trodelvy  in MTAP-deletion UC and clinical data update in 2025; expanded clinical study collaboration into NSCLC. \"We had multiple positive clinical updates across our pipeline throughout the past year that were presented at major medical conferences, including compelling results such as tumor shrinkage and eye preservation for neoadjuvant darovasertib which was presented as an oral presentation at ASCO 2024, and evidence for monotherapy activi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ideaya-biosciences-inc-reports-fourth-110500658.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ideaya-biosciences-inc-reports-fourth-110500658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4195","ADC","BK4097","OS","PFS","MSS","BK4113","IDYA","BK4211","BK4080","BK4231"],"gpt_icon":0},{"id":"2511591770","title":"Storytel Among 3 Companies Estimated To Be Trading Below Intrinsic Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2511591770","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511591770?lang=en_us&edition=fundamental","pubTime":"2025-02-13 15:02","pubTimestamp":1739430140,"startTime":"0","endTime":"0","summary":"In recent weeks, global markets have experienced fluctuations driven by tariff uncertainties and mixed economic data, with U.S. stocks ending lower despite strong earnings reports from a majority of S&P 500 companies. As investors navigate these volatile conditions, identifying undervalued stocks trading below their intrinsic value can offer potential opportunities for those looking to capitalize on market inefficiencies and long-term growth prospects.Storytel is trading at SEK92.75, significantly below its estimated fair value of SEK176.17, indicating potential undervaluation based on cash flows. The company is expected to achieve profitability within the next three years, with earnings forecasted to grow 80.72% annually, outpacing market averages. Recent collaboration with Vodafone Turkey expands Storytel's reach to over 20 million subscribers, potentially boosting revenue growth projected at 10% per year, well above the Swedish market rate of 1.1%.Giant Biogene Holding is trading at","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/storytel-among-3-companies-estimated-070220743.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KD","STRYF","BK4134","BK4211","IE00B66KJ199.SGD","PFS","SMWB","IE0031619046.USD","BK4195","IE00B19Z4B17.USD","IE00B7SZL793.SGD","BK4111","BK4023","BK4539"],"gpt_icon":0},{"id":"2511564610","title":"3 Companies Possibly Trading Below Estimated Fair Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2511564610","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511564610?lang=en_us&edition=fundamental","pubTime":"2025-02-13 13:02","pubTimestamp":1739422938,"startTime":"0","endTime":"0","summary":"As global markets navigate a complex landscape marked by tariff uncertainties and mixed economic signals, investors are closely monitoring the performance of major indices. With U.S. stocks experiencing slight declines amidst trade tensions and labor market shifts, the search for undervalued opportunities becomes increasingly relevant. In such a climate, identifying stocks that may be trading below their estimated fair value can offer potential advantages for investors looking to capitalize on market inefficiencies.Overview: Venustech Group Inc. offers network security products, trusted security management platforms, and specialized security services and solutions globally, with a market cap of CN21.26 billion.Operations: The company's revenue segments include network security products, trusted security management platforms, and specialized security services and solutions.Operations: The company generates revenue from its film products business segment, serving both domestic and intern","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-companies-possibly-trading-below-050218681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OTGLF","BK4211","BK4134","OTGLY","BK4085","IE00B66KJ199.SGD","IE00B7SZL793.SGD","IE0031619046.USD","KD","BK4023","BK4539","PFS","BK4195","IE00B19Z4B17.USD","SMWB"],"gpt_icon":0},{"id":"2510356549","title":"Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo","url":"https://stock-news.laohu8.com/highlight/detail?id=2510356549","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510356549?lang=en_us&edition=fundamental","pubTime":"2025-02-12 03:13","pubTimestamp":1739301234,"startTime":"0","endTime":"0","summary":"On Monday, Pfizer Inc. and Astellas Pharma Inc.   released additional follow-up results from the Phase 3 EV-302 trial  of Padcev plus Keytruda  in patients with previously untreated locally advanced or metastatic urothelial cancer .Also Read: Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID-19 Products Show Strength, Issues Strong FY25 Outlook. The results showed a sustained overall survival  and progression-free survival  benefit consistent with the findings of the primary analysis after an additional 12 months of follow-up .Results showed enfortumab vedotin plus pembrolizumab reduced the risk of death by 49% versus chemotherapy.The median OS was 33.8 months for the combination versus 15.9 months for chemotherapy.The OS benefit was observed in all prespecified subgroups, including cisplatin eligible and ineligible subgroups.The median PFS was 12.5 months for the combination versus 6.3 months for chemotherapy.In addition to longer follow-up data, an exploratory analysis evalu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-astellas-tout-encouraging-data-191354087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999002232.USD","MRK","ALPMY","LU0321505868.SGD","ALPMF","BK4585","BK4534","LU1057294990.SGD","SG9999002224.SGD","BK4007","LU0058720904.USD","BK4581","LU0868494617.USD","BK4211","LU0306807586.USD","SG9999011175.SGD","BK4568","LU1066051498.USD","LU0456855351.SGD","BK4533","SG9999003800.SGD","LU0321505439.SGD","BK4599","LU0122379950.USD","LU1894683348.USD","LU0225771236.USD","BK4550","LU0306806265.USD","BK4592","SG9999013999.USD","IE00BBT3K403.USD","LU0289739699.SGD","LU1894683264.USD","LU0170899867.USD","BK4195","PFS","LU1066053197.SGD","LU0985481810.HKD","SG9999001176.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","BK4097","IE0002270589.USD","LU1883839398.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU0225284248.USD","PFE","BK4588","OS","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2510738568","title":"Press Release: Provident Bank Strengthens Executive Leadership Team, Welcoming Chief Lending Officer to Advance Commercial Banking and Lending Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2510738568","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510738568?lang=en_us&edition=fundamental","pubTime":"2025-02-11 21:00","pubTimestamp":1739278800,"startTime":"0","endTime":"0","summary":"Provident Bank Strengthens Executive Leadership Team, Welcoming Chief Lending Officer to Advance Commercial Banking and Lending Strategy. ISELIN, N.J., Feb. 11, 2025  -- Provident Bank, a leading New Jersey-based financial institution, is pleased to announce the addition of Bill Fink as Executive Vice President, Chief Lending Officer, leading the commercial bank and the commercial lending growth strategy.\"I'm excited to begin a new chapter in my career where I can support Provident Bank's mission to redefine the super community banking space,\" said Bill Fink, Executive Vice President and Chief Lending Officer. \"With a strong foundation and clear momentum, I look forward to using my experience in commercial lending to drive growth, strengthen customer relationships, and foster a culture of innovation and excellence that supports Provident Bank's business strategy.\". Mr. Fink brings two decades of leadership experience at TD Bank, N.A., where he held key senior roles across regional and ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STRK","BK4195","BK4500","BK4595","BK4516","BK4211","BK4120","CPA","BK4596","BK4585","BK4600","PFS","BK4008","BK4023","TISI","BK4588"],"gpt_icon":1},{"id":"2510385742","title":"IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2510385742","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510385742?lang=en_us&edition=fundamental","pubTime":"2025-02-11 21:00","pubTimestamp":1739278800,"startTime":"0","endTime":"0","summary":"100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/11/3024098/0/en/IN8bio-Reports-Updated-Positive-Results-from-Phase-1-Trial-of-INB-100-in-Leukemia-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","HSCT","BK4539","INB","PFS","BK4139","CR","IE00B66KJ199.SGD","IE00B7SZL793.SGD","LU2065731478.USD","BK4097","BK4195","BK4006","BK4211","CRS","IE0031619046.USD","INAB","RIC","OS","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2510388876","title":"Hot Chili Confirms Major Cu-Au Porphyry Discovery at La Verde","url":"https://stock-news.laohu8.com/highlight/detail?id=2510388876","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510388876?lang=en_us&edition=fundamental","pubTime":"2025-02-11 20:00","pubTimestamp":1739275200,"startTime":"0","endTime":"0","summary":"Multiple new significant drill intersections underpin rapidly growing oxide andsulphide discovery.320 m grading 0.3% Cu and 0.1 g/t Au from 34 m to end-of-hole . including 134 m at 0.4% Cu and 0.2 g/t Au from 180 m depth. including 56 m at 0.5% Cu and 0.2 g/t Au from 258 m depth. including 38 m at 0.5% Cu and 0.2 g/t Au from 68 m depth. including 20 m at 0.5% Cu and 0.2 g/t Au from 62 m depth. 135.5 m grading 0.3% Cu and 0.1 g/t Au from 64 m to end-of-hole . 308 m grading 0.5% Cu, 0.3 g/t Au from 46 m to end-of-hole . 362 m grading 0.3% Cu, 0.1g/t Au from 28m to end-of-hole . More results coming – assays pending for seven additional holes; deeper diamond drilling planned. Following in the footsteps of our successes at Cortadera and Productora, we've secured full control of La Verde after years of strategic consolidation, finally allowing us unrestricted access to test this historically overlooked p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/hot-chili-confirms-major-cu-120000682.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hot-chili-confirms-major-cu-120000682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0130517989.USD","LU0072461881.USD","BK7110","LU2065171402.SGD","LU1668664300.SGD","BK4168","PFS","LU0106831901.USD","LU2065169927.USD","IE0002270589.USD","AIG","LU1201861249.SGD","LU0980610538.SGD","CMP.AU","BK4195","HHLKF","IE00B7SZLL34.SGD","BK4211","LU2065171311.SGD","BK4585","HCH.AU","LU0130102774.USD","BK7007","BK4566","LU2065170008.USD","LU0162691827.USD","LU0648001328.SGD","IE00B19Z3581.USD","BK4117","MRE.AU","BK4588","BK4110","BK4015","LU0477156953.USD","RC","CMP","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2510815573","title":"Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510815573","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510815573?lang=en_us&edition=fundamental","pubTime":"2025-02-11 06:00","pubTimestamp":1739224800,"startTime":"0","endTime":"0","summary":"Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of la/mUC. At nearly 30 months of follow-up in the Phase 3 EV-302 trial, the combination doubled median overall survival and progression-free survival compared to chemotherapy, with no new safety signals identified. NEW YORK & TOKYO, February 10, 2025----Pfizer Inc.  and Astellas Pharma Inc.  today announced additional follow-up results from the Phase 3 EV-302 clinical trial  evaluating the efficacy and safety of PADCEV  , a Nectin-4 directed antibody-drug conjugate, plus KEYTRUDA , a PD-1 inhibitor, in patients with previously untreated locally advanced or metastatic urothelial cancer . The results showed a sustained overall survival  and progression-free survival  benefit consistent with the findings of the primary analysis after an additional 12 months of follow-up .1,2 These data will be p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b68b91779c1270fe944d25cf0021e5aa","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-astellas-padcev-enfortumab-vedotin-220000915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU1699723380.USD","LU0861579265.USD","LU0985481810.HKD","LU0208291251.USD","BK4007","LU1037948897.HKD","SG9999013999.USD","LU2089984988.USD","IE00B66KJ199.SGD","IE00BLSP4239.USD","LU0234572021.USD","LU1585245621.USD","BK4559","LU1116320737.USD","LU0238689110.USD","BK4516","LU1929549753.HKD","BK4534","LU1983299246.USD","MRK","IE00B2B36J28.USD","LU0321505439.SGD","BK4097","BK4157","LU1093756168.USD","AST","LU1162221912.USD","LU0321505868.SGD","LU1023059063.AUD","IE0031619046.USD","PFS","LU0289739699.SGD","ALPMF","PFE","LU0320765646.SGD","LU1934455277.USD","ALT","OS","BK4080","TEN","BK4195","LU1934455863.HKD","AEIS","LU0122379950.USD","IE0009355771.USD","LU1571399168.USD","ADC","ALPMY","LU1883839398.USD","LU1057294990.SGD"],"gpt_icon":1},{"id":"2510968073","title":"Wildcat Resources Says Preliminary Feasibility Study 50% Complete for West Australian Lithium Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2510968073","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510968073?lang=en_us&edition=fundamental","pubTime":"2025-02-10 07:24","pubTimestamp":1739143473,"startTime":"0","endTime":"0","summary":"Wildcat Resources  said on Monday its Preliminary Feasibility Study  for the Tabba Tabba lithium project in West Australia is 50% complete, according to a Monday Australia bourse filing.Stage 2 metallurgical test work has reached 75%, while a geotechnical study confirms favorable open-pit parameters, added the filing.Scenario analysis on process plant throughput rates is underway including 4.5 million tonnes per annum, 2.2 million per tonne per annum, and single and staged ramp-up options.The company completed successful baseline environmental monitoring and survey program in 2024 and targeted surveys are scheduled for 2025, per the filing.The company reported a cash balance of AU$63.6 million on Dec. 31, 2024, allowing a fast-track development of Tabba Tabba, per the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","BK7507","BK7506","PFS","XKO.AU","BK7504","BK4211","BK7095","XJO.AU","WC8.AU","BK4195","PLS.AU"],"gpt_icon":1},{"id":"2509784871","title":"KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System","url":"https://stock-news.laohu8.com/highlight/detail?id=2509784871","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509784871?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:05","pubTimestamp":1738875900,"startTime":"0","endTime":"0","summary":"MAHWAH, N.J., February 06, 2025----KORU Medical Systems, Inc.  , a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin  therapy infusion system for use with a commercialized drug therapy.Additionally, the project will include a close collaboration with SCHOTT Pharma and is expected to be the first of multiple joint projects with SCHOTT, allowing KORU Medical to develop a platform infusion system that can integrate with both a vial and prefilled syringe. The innovative system will be developed using KORU Medical’s infusion technology along with SCHOTT TOPPAC prefillable polymer syringes .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/koru-medical-systems-announces-agreement-210500497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KORU","BK4211","BK4195","BK4082","PFS","KRMD"],"gpt_icon":0},{"id":"2509438229","title":"3 Dividend Stocks In US With Yields Up To 8.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509438229","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509438229?lang=en_us&edition=fundamental","pubTime":"2025-02-06 19:01","pubTimestamp":1738839684,"startTime":"0","endTime":"0","summary":"As major U.S. stock indexes hover near record highs, driven by a rally in chipmakers like Nvidia and Broadcom, investors are increasingly looking for stable income sources amidst the market's volatility and geopolitical developments. Dividend stocks, known for providing regular income through payouts, can be an attractive option in such an environment, offering potential yields that can complement capital gains from rising markets.Overview: Peoples Bancorp Inc., with a market cap of approximately $1.15 billion, operates as the holding company for Peoples Bank, offering a range of commercial and consumer banking products and services.Overview: DHT Holdings, Inc. owns and operates crude oil tankers through its subsidiaries in Monaco, Singapore, and Norway, with a market cap of approximately $1.91 billion.Operations: DHT Holdings generates its revenue primarily from its fleet of crude oil tankers, amounting to $583.76 million.DHT Holdings offers an attractive dividend yield of 8.39%, rank","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-dividend-stocks-us-yields-110124543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0256863811.USD","LU0942090050.USD","DHT","FMC","US6M.BOND","CVX","US5Y.BOND","LU0208291251.USD","US7Y.BOND","LU0070302665.USD","US30Y.BOND","DDS","LU0368265418.SGD","LU1929549753.HKD","LU0300736062.USD","LU0471298777.SGD","BK4201","BK4550","LU0320765489.SGD","US12M.BOND","LU0417517546.SGD","BK4534","LU0122376428.USD","LU0234572021.USD","LU1280957306.USD","PFS","LU0640476718.USD","BK4093","BK4559","LU1066051498.USD","LU2237438978.USD","LU0456854461.SGD","LU0788109394.HKD","LU0320765646.SGD","BK4588","US10Y.BOND","BK4220","LU1162221912.USD","LU1496350171.SGD","BK4103","LU0477156797.USD","LU0648000940.SGD","LU2133065610.SGD","BK4592","LU0868494708.USD","US3Y.BOND","IE00B2Q91V27.USD","PEBO","US2Y.BOND","BK4585","IPG"],"gpt_icon":0},{"id":"2509243379","title":"Resources Top 5: Investors pile in on AusQuest as it confirms copper-gold discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2509243379","media":"Stockheads","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509243379?lang=en_us&edition=fundamental","pubTime":"2025-02-06 13:51","pubTimestamp":1738821104,"startTime":"0","endTime":"0","summary":"AusQuest confirms large-scale discovery at Cangallo","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/02/pile-in--640x359.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/02/pile-in--640x359.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/resources/resources-top-5-investors-pile-in-on-ausquest-as-it-confirms-copper-gold-discovery/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4195","PFS","BK4211","ISBC"],"gpt_icon":0},{"id":"2509044100","title":"Akora Resources confirms DSO upgrade potential at Bekisopa iron ore project","url":"https://stock-news.laohu8.com/highlight/detail?id=2509044100","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509044100?lang=en_us&edition=fundamental","pubTime":"2025-02-05 10:01","pubTimestamp":1738720898,"startTime":"0","endTime":"0","summary":"Metallurgical test work on samples from Akora Resources’  flagship Bekisopa iron ore discovery in Madagascar has confirmed the ore’s upgrade potential and improved the company’s confidence in increasing the project’s mine life and tonnages.Bekisopa contains intermediate-grade direct shipping ore  mineralisation, which ranges in grade from 40% to 58% iron and typically sits adjacent to and underlying the identified high-grade DSO resource.The company prepared five samples from numerous drill core sections across the project’s northern, central and southern resource areas.Test work using basic dry magnetic separation techniques confirmed that material at a coarse crush product size averaging 52.8% iron could be upgraded to a lump product grading 59.2% at 80.8% recovery, while material averaging 50.3% iron could be upgraded to a 60.8% fines product at 88% recovery.The testing – part of the Bekisopa pre-feasibility study  due for release in March – provides the opportunity for Akora to inc","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Akora-Resources-ASX-AKO-Bekisopa-Pre-Feasibility-Study-Update.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Akora-Resources-ASX-AKO-Bekisopa-Pre-Feasibility-Study-Update.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/akora-resources-confirms-dso-upgrade-potential-bekisopa-iron-ore/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7129","AKO.AU","BK4195","BK4211","PFS"],"gpt_icon":0},{"id":"2509466090","title":"PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2509466090","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509466090?lang=en_us&edition=fundamental","pubTime":"2025-02-04 22:26","pubTimestamp":1738679160,"startTime":"0","endTime":"0","summary":"PfizerPFE announced positive top-line results from the progression-free survival  analysis of a late-stage study of its oncology drug, Braftovi , for treating patients with metastatic colorectal cancer  harboring a BRAF V600E mutation. Braftovi is an oral small-molecule kinase inhibitor that targetsBRAF V600E.The phase III BREAKWATER study is evaluating the candidate's safety and efficacy in combination with Eli Lilly’s LLY Erbitux  and chemotherapy  in mCRC patients harboring a BRAF V600E mutation.BRAF mutations are found in 8-12% of mCRC cases and are linked to a poorer prognosis. The BRAF V600E mutation is the most common and more than doubles the risk of death compared to patients without any mutation. Despite the high unmet need, no biomarker-driven therapies were approved for previously untreated BRAF V600E-mutant mCRC until December 2024. Thus, Pfizer has the first-mover advantage in t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfes-colorectal-cancer-drug-meets-142600063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0640476718.USD","LU1093756325.SGD","LLY","LU1066053197.SGD","IE00BBT3K403.USD","LU1868836757.USD","LU1023059063.AUD","LU0868494617.USD","LU2361044949.HKD","PFS","LU0097036916.USD","LU0354030438.USD","LU2361045086.USD","LU1291159041.SGD","ALNY","CSTL","IE00BK4W5M84.HKD","PFE","BK4581","IE00B19Z3B42.SGD","BK4516","LU0170899867.USD","LU0238689110.USD","LU0882574055.USD","LU1623119135.USD","LU1127390331.HKD","LU2491050154.USD","LU0114720955.EUR","LU1064131342.USD","LU1720051017.SGD","BK4007","LU1066051498.USD","LU1894683264.USD","LU2491049909.HKD","LU2237443895.HKD","BK4534","BK4588","LU2361044865.SGD","LU0079474960.USD","LU0306806265.USD","LU0471298694.HKD","SG9999002232.USD","LU0823416689.USD","ORR","IE0002141913.USD","LU2106854487.HKD","LU2324357040.USD","LU2237438978.USD","LU1280957306.USD","SGXZ99366536.SGD"],"gpt_icon":1},{"id":"2508458639","title":"RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2508458639","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508458639?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:00","pubTimestamp":1738670400,"startTime":"0","endTime":"0","summary":"The 80-patientplacebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer , testing the potentially enhancing effect of opaganib in patients with a poor prognosis. The study is being financially supported by Bayer  and the Ramsay Hospital Research Foundation, and will be led by Professor Lisa Horvath from Chris O'Brien Lifehouse and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group . The study will utilize a companion lipid biomarker test  to select mCRPC patients who have a poor prognosis due to standard of care treatment and who may benefit from an opaganib + darolutamide combination treatment approach. Primary endpoint will be improved 12-month radiographic progression-free survival . Prostate cancer  is the second most diagnosed cancer in the world, with around 1.5 million new cases per year, causing almost 400,000 deaths. People with mC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-announces-initiation-phase-2-120000083.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-announces-initiation-phase-2-120000083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AR","IE0031619046.USD","AEIS","IE00B66KJ199.SGD","BK4007","BK4192","BK4009","ADT","PC","BK4157","PFS","BK4195","IE00B19Z4B17.USD","IE00B7SZL793.SGD","BK4211","RDHL","BK4213","BK4209","BK4165","ASPR"],"gpt_icon":0},{"id":"2508345850","title":"Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2508345850","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508345850?lang=en_us&edition=fundamental","pubTime":"2025-02-04 19:45","pubTimestamp":1738669500,"startTime":"0","endTime":"0","summary":"Full-Year 2024 Revenues of $63.6 Billion, Reflecting 7% Year-over-Year Operational Growth. Excluding Contributions from Paxlovid and Comirnaty, Revenues Grew 12% Operationally. Full-Year 2024 Reported Diluted EPS of $1.41 and Adjusted Diluted EPS of $3.11. Fourth-Quarter 2024 Revenues of $17.8 Billion, Reflecting 21% Year-over-Year Operational Growth. Fourth-Quarter 2024 Reported Diluted EPS of $0.07 and Adjusted Diluted EPS of $0.63. On Track to Deliver Overall Net Cost Savings of Approximately $4.5 Billion by End of 2025 from Ongoing Cost Realignment Program. Reaffirms All Components of Full-Year 2025 Financial Guidance, including Revenues in a Range of $61.0 to $64.0 Billion and Adjusted Diluted EPS in a Range of $2.80 to $3.00. NEW YORK, February 04, 2025----Pfizer Inc.  reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance provided on December 17, 2024.The fourth-quarter 2024 earnings presentation and accompanying prepared rema","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e75b2b7dcb07c669b5aa92e4e319edbe","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-reports-strong-full-2024-114500880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","IE00B19Z3B42.SGD","LU0122379950.USD","MBC","PFS","BK4533","IE00BLSP4452.SGD","BK4195","LU0234572021.USD","SG9999001176.USD","LU0170899867.USD","LU1883839398.USD","BK4166","BK4548","BK4551","BNTX","BK4139","LU1066051498.USD","BCG","LU0306806265.USD","SG9999002232.USD","BK4135","BK4097","BK4211","BK4592","LU0225771236.USD","SGXZ57979304.SGD","IE00BLSP4239.USD","ORR","BK4599","BK4503","BK4581","BK4201","IE00BBT3K403.USD","LU0225284248.USD","SG9999001176.SGD","LU0058720904.USD","EC","LU1894683348.USD","OS","PFE","LU0306807586.USD","LU0321505868.SGD","SG9999002224.SGD","BK4535","QD","BK4568","LU0868494617.USD","LU0289739699.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PFS\",params:#limit:5,,,undefined,":[{"date":"2025-05-16","symbol":"PFS","amount":0.24,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-16","defaultRemindTime":1747402200000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-30","payableDate":"2025-05-16","currency":"USD","dateTimestamp":1747368000000,"payDate":"2025-05-30"},{"date":"2025-04-24","symbol":"PFS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.47,"defaultRemindTime":1745524800000,"name":null,"time":"Post Market","dateTimestamp":1745467200000,"actualEps":null},{"date":"2025-02-14","symbol":"PFS","amount":0.24,"announcedDate":"2025-01-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-14","defaultRemindTime":1739543400000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-28","payableDate":"2025-02-14","currency":"USD","dateTimestamp":1739509200000,"payDate":"2025-02-28"},{"market":"US","date":"2025-01-28","symbol":"PFS","fiscalQuarterEnding":"2024/12","expectedEps":0.5,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738040400000,"reportTimeType":"post","actualEps":0.37},{"date":"2024-11-15","symbol":"PFS","amount":0.24,"announcedDate":"2024-10-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-15","defaultRemindTime":1731681000000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-29","payableDate":"2024-11-15","currency":"USD","dateTimestamp":1731646800000,"payDate":"2024-11-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PFS\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-13","recordDate":"2015-05-15","paymentDate":"2015-05-29","value":0.16,"currency":"USD"},{"executeDate":"2015-08-12","recordDate":"2015-08-14","paymentDate":"2015-08-28","value":0.16,"currency":"USD"},{"executeDate":"2015-11-10","recordDate":"2015-11-13","paymentDate":"2015-11-27","value":0.17,"currency":"USD"},{"executeDate":"2016-02-10","recordDate":"2016-02-12","paymentDate":"2016-02-26","value":0.17,"currency":"USD"},{"executeDate":"2016-05-11","recordDate":"2016-05-13","paymentDate":"2016-05-31","value":0.18,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PFS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.8333,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1734148800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PFS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PFS","date":"2025-04-29","current":14.646015,"percent":0.743089,"low":6.410614,"twenty":8.698894,"median":10.357421,"eighty":16.512412,"high":33.980228,"avg":12.892668,"sd":6.39844,"marketCap":2159862431},"quantilePoints":[{"date":"2020-05-01","current":9.095426,"twenty":14.024503,"median":17.544322,"eighty":19.049774,"marketCap":879291222},{"date":"2020-05-08","current":8.942283,"twenty":13.850794,"median":17.544322,"eighty":19.049774,"marketCap":864486279},{"date":"2020-05-15","current":7.690497,"twenty":13.45386,"median":17.544322,"eighty":19.049774,"marketCap":743471074},{"date":"2020-05-22","current":8.31639,"twenty":13.355525,"median":17.544322,"eighty":19.049774,"marketCap":803978677},{"date":"2020-05-29","current":8.675946,"twenty":13.325105,"median":17.544322,"eighty":19.049774,"marketCap":838738363},{"date":"2020-06-05","current":10.060901,"twenty":13.301991,"median":17.544322,"eighty":19.049774,"marketCap":972627526},{"date":"2020-06-12","current":8.802456,"twenty":13.236148,"median":17.54157,"eighty":19.049774,"marketCap":850968623},{"date":"2020-06-19","current":8.702579,"twenty":13.220184,"median":17.524378,"eighty":19.049774,"marketCap":841313155},{"date":"2020-06-26","current":8.695921,"twenty":13.193521,"median":17.503783,"eighty":19.049774,"marketCap":840669457},{"date":"2020-07-02","current":9.022184,"twenty":13.181803,"median":17.497343,"eighty":19.049774,"marketCap":872210654},{"date":"2020-07-10","current":8.9556,"twenty":13.133798,"median":17.475453,"eighty":19.049774,"marketCap":865773675},{"date":"2020-07-17","current":9.375082,"twenty":13.113766,"median":17.448564,"eighty":19.049774,"marketCap":906326643},{"date":"2020-07-24","current":9.601469,"twenty":13.098537,"median":17.431245,"eighty":19.049774,"marketCap":928212371},{"date":"2020-07-31","current":10.146984,"twenty":13.0648,"median":17.422118,"eighty":19.049774,"marketCap":878647633},{"date":"2020-08-07","current":10.689643,"twenty":13.048711,"median":17.403942,"eighty":19.049774,"marketCap":925637580},{"date":"2020-08-14","current":10.527035,"twenty":13.031177,"median":17.388517,"eighty":19.049774,"marketCap":911556975},{"date":"2020-08-21","current":9.599052,"twenty":13.008395,"median":17.362339,"eighty":19.049774,"marketCap":831201106},{"date":"2020-08-28","current":9.947973,"twenty":12.988694,"median":17.334295,"eighty":19.049774,"marketCap":861414913},{"date":"2020-09-04","current":10.155841,"twenty":12.944965,"median":17.31872,"eighty":19.049774,"marketCap":879414627},{"date":"2020-09-11","current":9.509966,"twenty":12.926046,"median":17.247931,"eighty":19.049774,"marketCap":823486942},{"date":"2020-09-18","current":9.539661,"twenty":12.903594,"median":17.204455,"eighty":19.049774,"marketCap":826058330},{"date":"2020-09-25","current":8.916057,"twenty":12.85637,"median":17.165483,"eighty":19.049774,"marketCap":772059186},{"date":"2020-10-02","current":9.457999,"twenty":12.836682,"median":17.1464,"eighty":19.049774,"marketCap":818987014},{"date":"2020-10-09","current":9.777225,"twenty":12.825762,"median":17.106994,"eighty":19.030829,"marketCap":846629433},{"date":"2020-10-16","current":9.658443,"twenty":12.807943,"median":17.057235,"eighty":18.996004,"marketCap":836343881},{"date":"2020-10-23","current":10.222656,"twenty":12.774984,"median":17.027417,"eighty":18.941136,"marketCap":885200250},{"date":"2020-10-30","current":10.595048,"twenty":12.75677,"median":16.971439,"eighty":18.91343,"marketCap":872343311},{"date":"2020-11-06","current":10.696549,"twenty":12.723452,"median":16.947615,"eighty":18.891695,"marketCap":880700321},{"date":"2020-11-13","current":13.674488,"twenty":12.723452,"median":16.898923,"eighty":18.890505,"marketCap":1125888942},{"date":"2020-11-20","current":14.639195,"twenty":12.723452,"median":16.877422,"eighty":18.890505,"marketCap":1205318094},{"date":"2020-11-27","current":15.191794,"twenty":12.723452,"median":16.856678,"eighty":18.890505,"marketCap":1250816345},{"date":"2020-12-04","current":16.053474,"twenty":12.723452,"median":16.820466,"eighty":18.876273,"marketCap":1321762772},{"date":"2020-12-11","current":16.072206,"twenty":12.723452,"median":16.79439,"eighty":18.876273,"marketCap":1323305085},{"date":"2020-12-18","current":16.222063,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1335643594},{"date":"2020-12-24","current":16.718466,"twenty":12.723452,"median":16.730308,"eighty":18.876273,"marketCap":1376514905},{"date":"2020-12-31","current":16.821493,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1384997630},{"date":"2021-01-08","current":18.095281,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1489874956},{"date":"2021-01-15","current":17.992254,"twenty":12.723452,"median":16.744122,"eighty":18.876273,"marketCap":1481392232},{"date":"2021-01-22","current":18.142111,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1493730740},{"date":"2021-01-29","current":14.720538,"twenty":12.723452,"median":16.78893,"eighty":18.876273,"marketCap":1427170886},{"date":"2021-02-05","current":15.094115,"twenty":12.723452,"median":16.757917,"eighty":18.876273,"marketCap":1463389586},{"date":"2021-02-12","current":15.571023,"twenty":12.723452,"median":16.755695,"eighty":18.876273,"marketCap":1509626224},{"date":"2021-02-19","current":15.626662,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1515020498},{"date":"2021-02-26","current":16.079724,"twenty":12.723452,"median":16.714233,"eighty":18.876273,"marketCap":1558945304},{"date":"2021-03-05","current":17.794179,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1725163471},{"date":"2021-03-12","current":18.789768,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1821686827},{"date":"2021-03-19","current":18.215526,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1766013442},{"date":"2021-03-26","current":18.002063,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1745317972},{"date":"2021-04-01","current":17.749069,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1720790008},{"date":"2021-04-09","current":18.24715,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1769079438},{"date":"2021-04-16","current":18.405271,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1784409415},{"date":"2021-04-23","current":18.674076,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1810470378},{"date":"2021-04-30","current":14.042944,"twenty":12.721872,"median":16.669814,"eighty":18.884491,"marketCap":1833713567},{"date":"2021-05-07","current":15.049841,"twenty":12.721872,"median":16.625436,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-05-14","current":15.169001,"twenty":12.721872,"median":16.591954,"eighty":18.884491,"marketCap":1980752967},{"date":"2021-05-21","current":15.133253,"twenty":12.721872,"median":16.545238,"eighty":18.884491,"marketCap":1976085049},{"date":"2021-05-28","current":15.049841,"twenty":12.721872,"median":16.529666,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-06-04","current":15.043883,"twenty":12.721872,"median":16.506308,"eighty":18.884491,"marketCap":1964415256},{"date":"2021-06-11","current":14.722153,"twenty":12.721872,"median":16.44402,"eighty":18.884491,"marketCap":1922403999},{"date":"2021-06-18","current":13.679507,"twenty":12.721872,"median":16.40509,"eighty":18.884491,"marketCap":1786256407},{"date":"2021-06-25","current":14.227641,"twenty":12.721872,"median":16.3245,"eighty":18.884491,"marketCap":1857831141},{"date":"2021-07-02","current":13.500768,"twenty":12.721872,"median":16.302281,"eighty":18.884491,"marketCap":1762916819},{"date":"2021-07-09","current":13.244575,"twenty":12.721872,"median":16.261288,"eighty":18.884491,"marketCap":1729463411},{"date":"2021-07-16","current":12.976467,"twenty":12.721872,"median":16.250162,"eighty":18.884491,"marketCap":1694454030},{"date":"2021-07-23","current":12.55345,"twenty":12.69964,"median":16.222063,"eighty":18.884491,"marketCap":1639217007},{"date":"2021-07-30","current":10.433885,"twenty":12.684833,"median":16.184117,"eighty":18.884491,"marketCap":1680450278},{"date":"2021-08-06","current":10.849309,"twenty":12.675728,"median":16.148152,"eighty":18.884491,"marketCap":1747357095},{"date":"2021-08-13","current":10.552042,"twenty":12.660863,"median":16.109223,"eighty":18.884491,"marketCap":1699480276},{"date":"2021-08-20","current":10.381313,"twenty":12.614911,"median":16.079724,"eighty":18.884491,"marketCap":1671983067},{"date":"2021-08-27","current":10.571012,"twenty":12.560516,"median":16.051403,"eighty":18.884491,"marketCap":1702535521},{"date":"2021-09-03","current":10.362343,"twenty":12.528973,"median":16.012247,"eighty":18.884491,"marketCap":1668927821},{"date":"2021-09-10","current":10.43348,"twenty":12.478039,"median":15.976834,"eighty":18.884491,"marketCap":1680384992},{"date":"2021-09-17","current":10.542557,"twenty":12.463634,"median":15.915973,"eighty":18.884491,"marketCap":1697952653},{"date":"2021-09-24","current":10.841334,"twenty":12.367008,"median":15.852207,"eighty":18.884491,"marketCap":1746072768},{"date":"2021-10-01","current":11.315583,"twenty":12.317066,"median":15.827979,"eighty":18.884491,"marketCap":1822453904},{"date":"2021-10-08","current":11.718695,"twenty":12.271397,"median":15.788905,"eighty":18.884491,"marketCap":1887377870},{"date":"2021-10-15","current":11.713953,"twenty":12.250326,"median":15.716295,"eighty":18.884491,"marketCap":1886614059},{"date":"2021-10-22","current":11.808802,"twenty":12.188782,"median":15.680935,"eighty":18.884491,"marketCap":1901890286},{"date":"2021-10-29","current":11.169949,"twenty":12.144658,"median":15.649322,"eighty":18.884491,"marketCap":1912127768},{"date":"2021-11-05","current":11.584988,"twenty":12.022084,"median":15.636232,"eighty":18.884491,"marketCap":1983176134},{"date":"2021-11-12","current":11.413559,"twenty":11.87183,"median":15.555472,"eighty":18.877325,"marketCap":1953830070},{"date":"2021-11-19","current":11.06619,"twenty":11.803248,"median":15.475641,"eighty":18.822017,"marketCap":1894365677},{"date":"2021-11-26","current":10.935362,"twenty":11.752841,"median":15.361209,"eighty":18.799671,"marketCap":1871969996},{"date":"2021-12-03","current":10.660174,"twenty":11.700674,"median":15.25837,"eighty":18.766081,"marketCap":1824861840},{"date":"2021-12-10","current":10.64664,"twenty":11.597269,"median":15.189807,"eighty":18.713257,"marketCap":1822545046},{"date":"2021-12-17","current":10.745888,"twenty":11.515514,"median":15.166494,"eighty":18.654746,"marketCap":1839534872},{"date":"2021-12-23","current":10.957919,"twenty":11.442431,"median":15.126556,"eighty":18.639247,"marketCap":1875831320},{"date":"2021-12-31","current":10.92634,"twenty":11.368446,"median":15.085589,"eighty":18.621596,"marketCap":1870425466},{"date":"2022-01-07","current":11.738372,"twenty":11.326022,"median":15.058778,"eighty":18.579091,"marketCap":2009433139},{"date":"2022-01-14","current":11.729349,"twenty":11.326022,"median":15.040904,"eighty":18.531427,"marketCap":2007888610},{"date":"2022-01-21","current":10.863182,"twenty":11.299875,"median":15.028989,"eighty":18.489553,"marketCap":1859613758},{"date":"2022-01-28","current":11.023748,"twenty":11.261979,"median":15.001772,"eighty":18.453467,"marketCap":1851118845},{"date":"2022-02-04","current":11.088134,"twenty":11.181448,"median":14.930112,"eighty":18.423167,"marketCap":1861930553},{"date":"2022-02-11","current":10.92717,"twenty":11.115728,"median":14.912327,"eighty":18.41438,"marketCap":1834901283},{"date":"2022-02-18","current":10.92717,"twenty":11.065654,"median":14.87528,"eighty":18.386528,"marketCap":1834901283},{"date":"2022-02-25","current":10.732094,"twenty":11.023748,"median":14.820597,"eighty":18.371521,"marketCap":1802143926},{"date":"2022-03-04","current":10.629654,"twenty":11.007105,"median":14.772796,"eighty":18.349914,"marketCap":1784942161},{"date":"2022-03-11","current":10.652348,"twenty":10.957288,"median":14.734826,"eighty":18.315942,"marketCap":1788752883},{"date":"2022-03-18","current":10.806664,"twenty":10.92634,"median":14.709739,"eighty":18.308123,"marketCap":1814665792},{"date":"2022-03-25","current":10.720428,"twenty":10.866543,"median":14.669048,"eighty":18.291682,"marketCap":1800185049},{"date":"2022-04-01","current":10.629654,"twenty":10.847714,"median":14.635382,"eighty":18.253335,"marketCap":1784942161},{"date":"2022-04-08","current":10.053238,"twenty":10.819838,"median":14.583758,"eighty":18.229989,"marketCap":1688149823},{"date":"2022-04-14","current":10.071393,"twenty":10.805336,"median":14.512906,"eighty":18.210171,"marketCap":1691198401},{"date":"2022-04-22","current":10.171245,"twenty":10.764,"median":14.497563,"eighty":18.192392,"marketCap":1707965577},{"date":"2022-04-29","current":10.150722,"twenty":10.733654,"median":14.451873,"eighty":18.177577,"marketCap":1657856535},{"date":"2022-05-06","current":10.297502,"twenty":10.713769,"median":14.383195,"eighty":18.14275,"marketCap":1681829155},{"date":"2022-05-13","current":9.954658,"twenty":10.67461,"median":14.304676,"eighty":18.117189,"marketCap":1625834598},{"date":"2022-05-20","current":10.078233,"twenty":10.650249,"median":14.249341,"eighty":18.096905,"marketCap":1646017372},{"date":"2022-05-27","current":10.572534,"twenty":10.629654,"median":14.193648,"eighty":18.064002,"marketCap":1726748469},{"date":"2022-06-03","current":10.412344,"twenty":10.620376,"median":14.117725,"eighty":18.057139,"marketCap":1700585614},{"date":"2022-06-10","current":10.000427,"twenty":10.605236,"median":13.994542,"eighty":18.016495,"marketCap":1633309699},{"date":"2022-06-17","current":9.92262,"twenty":10.570637,"median":13.872371,"eighty":17.998745,"marketCap":1620602026},{"date":"2022-06-24","current":10.165194,"twenty":10.552314,"median":13.685465,"eighty":17.991294,"marketCap":1660220065},{"date":"2022-07-01","current":10.513034,"twenty":10.530137,"median":13.611721,"eighty":17.968495,"marketCap":1717030837},{"date":"2022-07-08","current":10.31623,"twenty":10.524934,"median":13.456373,"eighty":17.95339,"marketCap":1684887900},{"date":"2022-07-15","current":10.288769,"twenty":10.512341,"median":13.392091,"eighty":17.910649,"marketCap":1680402839},{"date":"2022-07-22","current":10.613725,"twenty":10.505887,"median":13.327225,"eighty":17.849237,"marketCap":1733476061},{"date":"2022-07-29","current":11.467199,"twenty":10.505887,"median":13.302306,"eighty":17.813962,"marketCap":1809111112},{"date":"2022-08-05","current":11.377758,"twenty":10.505887,"median":13.239282,"eighty":17.786291,"marketCap":1795000639},{"date":"2022-08-12","current":11.739288,"twenty":10.505887,"median":13.221695,"eighty":17.762714,"marketCap":1852037025},{"date":"2022-08-19","current":11.748717,"twenty":10.505887,"median":13.209959,"eighty":17.748875,"marketCap":1853524605},{"date":"2022-08-26","current":11.296118,"twenty":10.505887,"median":13.188531,"eighty":17.733901,"marketCap":1782120768},{"date":"2022-09-02","current":10.848234,"twenty":10.505887,"median":13.150076,"eighty":17.684237,"marketCap":1711460720},{"date":"2022-09-09","current":10.928381,"twenty":10.505887,"median":13.130958,"eighty":17.66138,"marketCap":1724105150},{"date":"2022-09-16","current":11.036817,"twenty":10.505887,"median":13.113536,"eighty":17.644475,"marketCap":1741212319},{"date":"2022-09-23","current":10.980242,"twenty":10.505887,"median":13.081395,"eighty":17.623016,"marketCap":1732286840},{"date":"2022-09-30","current":9.193418,"twenty":10.478391,"median":13.065324,"eighty":17.59628,"marketCap":1450390441},{"date":"2022-10-07","current":9.075554,"twenty":10.469523,"median":13.052449,"eighty":17.561143,"marketCap":1431795692},{"date":"2022-10-14","current":9.580013,"twenty":10.437974,"median":13.034632,"eighty":17.546569,"marketCap":1511381219},{"date":"2022-10-21","current":9.716736,"twenty":10.425892,"median":13.011756,"eighty":17.514492,"marketCap":1532951128},{"date":"2022-10-28","current":10.271339,"twenty":10.389888,"median":12.992653,"eighty":17.479985,"marketCap":1683636796},{"date":"2022-11-04","current":10.266754,"twenty":10.377223,"median":12.955005,"eighty":17.444428,"marketCap":1682885173},{"date":"2022-11-11","current":10.291061,"twenty":10.357421,"median":12.934931,"eighty":17.408903,"marketCap":1686869566},{"date":"2022-11-18","current":10.064186,"twenty":10.320716,"median":12.924436,"eighty":17.359105,"marketCap":1649681083},{"date":"2022-11-25","current":10.272911,"twenty":10.310098,"median":12.883192,"eighty":17.323674,"marketCap":1683894487},{"date":"2022-12-02","current":10.204848,"twenty":10.293993,"median":12.857307,"eighty":17.216387,"marketCap":1672737942},{"date":"2022-12-09","current":9.973436,"twenty":10.282719,"median":12.842174,"eighty":17.162345,"marketCap":1634805690},{"date":"2022-12-16","current":9.360873,"twenty":10.269156,"median":12.829982,"eighty":17.036971,"marketCap":1534396787},{"date":"2022-12-23","current":9.719335,"twenty":10.253097,"median":12.811402,"eighty":16.964208,"marketCap":1593154590},{"date":"2022-12-30","current":9.69211,"twenty":10.230259,"median":12.79325,"eighty":16.866633,"marketCap":1588691972},{"date":"2023-01-06","current":9.896298,"twenty":10.216454,"median":12.770698,"eighty":16.761899,"marketCap":1622161606},{"date":"2023-01-13","current":10.150398,"twenty":10.193425,"median":12.743914,"eighty":16.690368,"marketCap":1663812707},{"date":"2023-01-20","current":10.213923,"twenty":10.187062,"median":12.725033,"eighty":16.523587,"marketCap":1674225482},{"date":"2023-01-27","current":9.790009,"twenty":10.173843,"median":12.690346,"eighty":16.324736,"marketCap":1719595430},{"date":"2023-02-03","current":10.396723,"twenty":10.16752,"median":12.677807,"eighty":16.256402,"marketCap":1826163591},{"date":"2023-02-10","current":10.238158,"twenty":10.16752,"median":12.667312,"eighty":16.23143,"marketCap":1798311961},{"date":"2023-02-17","current":10.259586,"twenty":10.15802,"median":12.637027,"eighty":16.127135,"marketCap":1802075695},{"date":"2023-02-24","current":10.011024,"twenty":10.149032,"median":12.580612,"eighty":16.062409,"marketCap":1758416384},{"date":"2023-03-03","current":9.946656,"twenty":10.12732,"median":12.54984,"eighty":16.029311,"marketCap":1747110222},{"date":"2023-03-10","current":8.806492,"twenty":10.110262,"median":12.491259,"eighty":15.99002,"marketCap":1546842669},{"date":"2023-03-17","current":8.551231,"twenty":10.087476,"median":12.467781,"eighty":15.924154,"marketCap":1502006690},{"date":"2023-03-24","current":8.308734,"twenty":10.075497,"median":12.378703,"eighty":15.861307,"marketCap":1459412470},{"date":"2023-03-31","current":8.159832,"twenty":10.060803,"median":12.352386,"eighty":15.839714,"marketCap":1433258125},{"date":"2023-04-06","current":7.704617,"twenty":10.04356,"median":12.287536,"eighty":15.796939,"marketCap":1353300555},{"date":"2023-04-14","current":7.832247,"twenty":10.027135,"median":12.261119,"eighty":15.730693,"marketCap":1375718565},{"date":"2023-04-21","current":7.74716,"twenty":10.017452,"median":12.211348,"eighty":15.694,"marketCap":1360773225},{"date":"2023-04-28","current":7.593207,"twenty":9.999766,"median":12.160062,"eighty":15.664957,"marketCap":1307717267},{"date":"2023-05-05","current":6.573548,"twenty":9.989771,"median":12.09154,"eighty":15.642667,"marketCap":1132109520},{"date":"2023-05-12","current":6.495446,"twenty":9.971621,"median":11.987273,"eighty":15.600987,"marketCap":1118658713},{"date":"2023-05-19","current":7.029498,"twenty":9.961387,"median":11.888242,"eighty":15.530275,"marketCap":1210634281},{"date":"2023-05-26","current":7.046909,"twenty":9.952827,"median":11.808802,"eighty":15.39865,"marketCap":1213632756},{"date":"2023-06-02","current":7.116551,"twenty":9.943684,"median":11.780347,"eighty":15.324881,"marketCap":1225626656},{"date":"2023-06-09","current":7.90873,"twenty":9.929925,"median":11.738372,"eighty":15.203096,"marketCap":1362057268},{"date":"2023-06-16","current":7.934846,"twenty":9.905841,"median":11.713953,"eighty":15.174007,"marketCap":1366554981},{"date":"2023-06-23","current":7.221014,"twenty":9.886325,"median":11.649929,"eighty":15.134319,"marketCap":1243617506},{"date":"2023-06-30","current":7.260188,"twenty":9.866996,"median":11.584988,"eighty":15.109317,"marketCap":1250364075},{"date":"2023-07-07","current":6.946798,"twenty":9.848756,"median":11.548897,"eighty":15.068412,"marketCap":1196391525},{"date":"2023-07-14","current":7.499583,"twenty":9.820363,"median":11.505283,"eighty":15.049841,"marketCap":1291593106},{"date":"2023-07-21","current":8.108951,"twenty":9.78572,"median":11.467199,"eighty":15.032889,"marketCap":1396539731},{"date":"2023-07-28","current":8.682159,"twenty":9.742349,"median":11.428126,"eighty":15.003286,"marketCap":1432521431},{"date":"2023-08-04","current":8.409258,"twenty":9.731294,"median":11.387173,"eighty":14.9415,"marketCap":1387493907},{"date":"2023-08-11","current":8.120111,"twenty":9.718285,"median":11.354912,"eighty":14.916422,"marketCap":1339785831},{"date":"2023-08-18","current":7.624539,"twenty":9.704927,"median":11.300777,"eighty":14.879018,"marketCap":1258018387},{"date":"2023-08-25","current":7.506329,"twenty":9.663774,"median":11.282731,"eighty":14.826043,"marketCap":1238514226},{"date":"2023-09-01","current":7.492689,"twenty":9.624389,"median":11.244446,"eighty":14.781733,"marketCap":1236263745},{"date":"2023-09-08","current":7.310828,"twenty":9.599052,"median":11.197237,"eighty":14.751943,"marketCap":1206257344},{"date":"2023-09-15","current":7.388119,"twenty":9.572255,"median":11.168825,"eighty":14.716388,"marketCap":1219010065},{"date":"2023-09-22","current":6.997117,"twenty":9.538302,"median":11.11225,"eighty":14.678775,"marketCap":1154496301},{"date":"2023-09-29","current":6.951652,"twenty":9.501581,"median":11.06619,"eighty":14.644899,"marketCap":1146994701},{"date":"2023-10-06","current":6.951652,"twenty":9.471361,"median":11.046743,"eighty":14.595078,"marketCap":1146994701},{"date":"2023-10-13","current":6.792523,"twenty":9.431033,"median":11.012054,"eighty":14.515019,"marketCap":1120739099},{"date":"2023-10-20","current":6.542463,"twenty":9.372419,"median":10.980475,"eighty":14.499896,"marketCap":1079480297},{"date":"2023-10-27","current":7.170747,"twenty":9.358917,"median":10.957919,"eighty":14.471655,"marketCap":1076479657},{"date":"2023-11-03","current":7.537213,"twenty":9.227549,"median":10.936586,"eighty":14.399708,"marketCap":1131493992},{"date":"2023-11-10","current":7.179977,"twenty":9.151165,"median":10.92634,"eighty":14.31961,"marketCap":1077865333},{"date":"2023-11-17","current":7.734589,"twenty":9.108811,"median":10.883634,"eighty":14.267749,"marketCap":1161124242},{"date":"2023-11-24","current":7.594687,"twenty":9.078197,"median":10.857,"eighty":14.214839,"marketCap":1140121995},{"date":"2023-12-01","current":7.60468,"twenty":8.976162,"median":10.840069,"eighty":14.143037,"marketCap":1141622155},{"date":"2023-12-08","current":8.214253,"twenty":8.928966,"median":10.82028,"eighty":14.03685,"marketCap":1233131947},{"date":"2023-12-15","current":9.103631,"twenty":8.896863,"median":10.805953,"eighty":13.930523,"marketCap":1366646233},{"date":"2023-12-22","current":9.083645,"twenty":8.896863,"median":10.78687,"eighty":13.759594,"marketCap":1363645912},{"date":"2023-12-29","current":9.223547,"twenty":8.892939,"median":10.761277,"eighty":13.668342,"marketCap":1384648159},{"date":"2024-01-05","current":8.743883,"twenty":8.862382,"median":10.745888,"eighty":13.56351,"marketCap":1312640455},{"date":"2024-01-12","current":8.583995,"twenty":8.806492,"median":10.720428,"eighty":13.408162,"marketCap":1288637886},{"date":"2024-01-19","current":8.309187,"twenty":8.772881,"median":10.697142,"eighty":13.342249,"marketCap":1247383472},{"date":"2024-01-26","current":8.828824,"twenty":8.752732,"median":10.656886,"eighty":13.316627,"marketCap":1325391819},{"date":"2024-02-02","current":9.490046,"twenty":8.752732,"median":10.64215,"eighty":13.30073,"marketCap":1218502920},{"date":"2024-02-09","current":8.830529,"twenty":8.752732,"median":10.629654,"eighty":13.236743,"marketCap":1133822213},{"date":"2024-02-16","current":9.326626,"twenty":8.752732,"median":10.620577,"eighty":13.221244,"marketCap":1197520090},{"date":"2024-02-23","current":8.865547,"twenty":8.752732,"median":10.61055,"eighty":13.209959,"marketCap":1138318534},{"date":"2024-03-01","current":8.801346,"twenty":8.74965,"median":10.589265,"eighty":13.19135,"marketCap":1130075279},{"date":"2024-03-08","current":8.986315,"twenty":8.743883,"median":10.567288,"eighty":13.154274,"marketCap":1153824926},{"date":"2024-03-15","current":8.329352,"twenty":8.723902,"median":10.538449,"eighty":13.128485,"marketCap":1069472190},{"date":"2024-03-22","current":8.96157,"twenty":8.698898,"median":10.5269,"eighty":13.112465,"marketCap":1150647615},{"date":"2024-03-28","current":8.466976,"twenty":8.693607,"median":10.517516,"eighty":13.098537,"marketCap":1087142753},{"date":"2024-04-05","current":8.466976,"twenty":8.653336,"median":10.488954,"eighty":13.065324,"marketCap":1087142753},{"date":"2024-04-12","current":7.990046,"twenty":8.61897,"median":10.476162,"eighty":13.052449,"marketCap":1025905922},{"date":"2024-04-19","current":8.671317,"twenty":8.578848,"median":10.466677,"eighty":13.034632,"marketCap":1040072426},{"date":"2024-04-26","current":9.585747,"twenty":8.579877,"median":10.437517,"eighty":13.020302,"marketCap":1149752791},{"date":"2024-05-03","current":9.605463,"twenty":8.579877,"median":10.431596,"eighty":12.999364,"marketCap":1152117669},{"date":"2024-05-10","current":10.091416,"twenty":8.579877,"median":10.40199,"eighty":12.962642,"marketCap":1210404831},{"date":"2024-05-17","current":10.167149,"twenty":8.579877,"median":10.387579,"eighty":12.944965,"marketCap":1219488545},{"date":"2024-05-24","current":9.554974,"twenty":8.579877,"median":10.368229,"eighty":12.926046,"marketCap":1146061860},{"date":"2024-05-31","current":9.031155,"twenty":8.579877,"median":10.357421,"eighty":12.90972,"marketCap":1083232842},{"date":"2024-06-07","current":8.639868,"twenty":8.579877,"median":10.32448,"eighty":12.882781,"marketCap":1036300321},{"date":"2024-06-14","current":8.494713,"twenty":8.57296,"median":10.31623,"eighty":12.877209,"marketCap":1018889870},{"date":"2024-06-21","current":8.53258,"twenty":8.56142,"median":10.296725,"eighty":12.877995,"marketCap":1023431727},{"date":"2024-06-28","current":8.608313,"twenty":8.557426,"median":10.288769,"eighty":12.87427,"marketCap":1032515441},{"date":"2024-07-05","current":9.17631,"twenty":8.557426,"median":10.28051,"eighty":12.856219,"marketCap":1100643293},{"date":"2024-07-12","current":10.066172,"twenty":8.557426,"median":10.267199,"eighty":12.83418,"marketCap":1207376927},{"date":"2024-07-15","current":10.141905,"twenty":8.557426,"median":10.266754,"eighty":12.829982,"marketCap":1216460640},{"date":"2024-08-02","current":30.236968,"twenty":8.550513,"median":10.244363,"eighty":12.813454,"marketCap":2311767376},{"date":"2024-08-09","current":28.994819,"twenty":8.550513,"median":10.244363,"eighty":12.829982,"marketCap":2216798880},{"date":"2024-08-16","current":30.839915,"twenty":8.550513,"median":10.244363,"eighty":12.847792,"marketCap":2357865738},{"date":"2024-08-23","current":30.942317,"twenty":8.550513,"median":10.244363,"eighty":12.868391,"marketCap":2365694844},{"date":"2024-08-30","current":32.290603,"twenty":8.550513,"median":10.244363,"eighty":12.926535,"marketCap":2468778073},{"date":"2024-09-06","current":31.86393,"twenty":8.550513,"median":10.244363,"eighty":12.95098,"marketCap":2436156798},{"date":"2024-09-13","current":30.379109,"twenty":8.550513,"median":10.244363,"eighty":12.978743,"marketCap":2322634762},{"date":"2024-09-20","current":33.178083,"twenty":8.550513,"median":10.244363,"eighty":12.986356,"marketCap":2536630324},{"date":"2024-09-27","current":30.92525,"twenty":8.550513,"median":10.244363,"eighty":13.030742,"marketCap":2364389993},{"date":"2024-10-04","current":30.174306,"twenty":8.550513,"median":10.244363,"eighty":13.065239,"marketCap":2306976550},{"date":"2024-10-11","current":30.874049,"twenty":8.550513,"median":10.244363,"eighty":13.110396,"marketCap":2360475440},{"date":"2024-10-18","current":33.980228,"twenty":8.550513,"median":10.244363,"eighty":13.135891,"marketCap":2597958321},{"date":"2024-10-25","current":32.512473,"twenty":8.550513,"median":10.244363,"eighty":13.18261,"marketCap":2485741135},{"date":"2024-10-31","current":26.328623,"twenty":8.550513,"median":10.244363,"eighty":13.18261,"marketCap":2483131433},{"date":"2024-11-08","current":29.275547,"twenty":8.550153,"median":10.241149,"eighty":13.17502,"marketCap":2761064694},{"date":"2024-11-15","current":29.635999,"twenty":8.550153,"median":10.241149,"eighty":13.220364,"marketCap":2795059964},{"date":"2024-11-22","current":28.847366,"twenty":8.550153,"median":10.241149,"eighty":13.27236,"marketCap":2720681617},{"date":"2024-11-29","current":29.220929,"twenty":8.550153,"median":10.241149,"eighty":13.402862,"marketCap":2755913466},{"date":"2024-12-06","current":28.529146,"twenty":8.550153,"median":10.241149,"eighty":13.662197,"marketCap":2690669302},{"date":"2024-12-13","current":28.10024,"twenty":8.550153,"median":10.241149,"eighty":13.941658,"marketCap":2650217921},{"date":"2024-12-20","current":25.789683,"twenty":8.550153,"median":10.241149,"eighty":14.183552,"marketCap":2432302415},{"date":"2024-12-27","current":26.509138,"twenty":8.550153,"median":10.241149,"eighty":14.332934,"marketCap":2500156345},{"date":"2025-01-03","current":25.734341,"twenty":8.550153,"median":10.241149,"eighty":14.482787,"marketCap":2427082882},{"date":"2025-01-10","current":25.720505,"twenty":8.549794,"median":10.239653,"eighty":14.532851,"marketCap":2425777998},{"date":"2025-01-17","current":26.619823,"twenty":8.549794,"median":10.239653,"eighty":14.674786,"marketCap":2510595411},{"date":"2025-01-24","current":26.24626,"twenty":8.549794,"median":10.239653,"eighty":14.756709,"marketCap":2475363563},{"date":"2025-01-31","current":20.963976,"twenty":8.549794,"median":10.239653,"eighty":14.865144,"marketCap":2421863349},{"date":"2025-02-07","current":22.127386,"twenty":8.549794,"median":10.239653,"eighty":14.930454,"marketCap":2556266325},{"date":"2025-02-14","current":21.3819,"twenty":8.549794,"median":10.239653,"eighty":15.030776,"marketCap":2470144030},{"date":"2025-02-21","current":20.6703,"twenty":8.549794,"median":10.239653,"eighty":15.049841,"marketCap":2387936384},{"date":"2025-02-28","current":20.24108,"twenty":8.549794,"median":10.239653,"eighty":15.119808,"marketCap":2338350819},{"date":"2025-03-07","current":19.574836,"twenty":8.549435,"median":10.238158,"eighty":15.219892,"marketCap":2261382913},{"date":"2025-03-14","current":18.818048,"twenty":8.556094,"median":10.256731,"eighty":15.427951,"marketCap":2173954953},{"date":"2025-03-21","current":19.168203,"twenty":8.563982,"median":10.270461,"eighty":15.642559,"marketCap":2214406696},{"date":"2025-03-28","current":19.642608,"twenty":8.589386,"median":10.284192,"eighty":15.976834,"marketCap":2269212283},{"date":"2025-04-04","current":18.08385,"twenty":8.61897,"median":10.295948,"eighty":16.156501,"marketCap":2089136782},{"date":"2025-04-11","current":16.76376,"twenty":8.629342,"median":10.308893,"eighty":16.250162,"marketCap":1936633430},{"date":"2025-04-17","current":17.215614,"twenty":8.672243,"median":10.320508,"eighty":16.320056,"marketCap":1988833792},{"date":"2025-04-25","current":14.956124,"twenty":8.693028,"median":10.339114,"eighty":16.512412,"marketCap":2205594545},{"date":"2025-04-29","current":14.646015,"twenty":8.698894,"median":10.357421,"eighty":16.512412,"marketCap":2159862431}],"updateTime":1746030348826}}}